These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27251573)

  • 1. Immuno-targeting the multifunctional CD38 using nanobody.
    Li T; Qi S; Unger M; Hou YN; Deng QW; Liu J; Lam CMC; Wang XW; Xin D; Zhang P; Koch-Nolte F; Hao Q; Zhang H; Lee HC; Zhao YJ
    Sci Rep; 2016 Jun; 6():27055. PubMed ID: 27251573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
    Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
    Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
    [No Abstract]   [Full Text] [Related]  

  • 3. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38
    Fumey W; Koenigsdorf J; Kunick V; Menzel S; Schütze K; Unger M; Schriewer L; Haag F; Adam G; Oberle A; Binder M; Fliegert R; Guse A; Zhao YJ; Cheung Lee H; Malavasi F; Goldbaum F; van Hegelsom R; Stortelers C; Bannas P; Koch-Nolte F
    Sci Rep; 2017 Oct; 7(1):14289. PubMed ID: 29084989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
    Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2553. PubMed ID: 30524421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanobody-based dual epitopes protein identification (DepID) assay for measuring soluble CD38 in plasma of multiple myeloma patients.
    Li T; Li SL; Fang C; Hou YN; Zhang Q; Du X; Lee HC; Zhao YJ
    Anal Chim Acta; 2018 Oct; 1029():65-71. PubMed ID: 29907292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells.
    Hambach J; Fumey W; Stähler T; Gebhardt AJ; Adam G; Weisel K; Koch-Nolte F; Bannas P
    Front Immunol; 2022; 13():838406. PubMed ID: 35651607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs).
    Hambach J; Riecken K; Cichutek S; Schütze K; Albrecht B; Petry K; Röckendorf JL; Baum N; Kröger N; Hansen T; Schuch G; Haag F; Adam G; Fehse B; Bannas P; Koch-Nolte F
    Cells; 2020 Jan; 9(2):. PubMed ID: 32013131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.
    An N; Hou YN; Zhang QX; Li T; Zhang QL; Fang C; Chen H; Lee HC; Zhao YJ; Du X
    Mol Pharm; 2018 Oct; 15(10):4577-4588. PubMed ID: 30185037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daratumumab in multiple myeloma.
    Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
    Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.
    Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2559. PubMed ID: 30459772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells.
    Baum N; Eggers M; Koenigsdorf J; Menzel S; Hambach J; Staehler T; Fliegert R; Kulow F; Adam G; Haag F; Bannas P; Koch-Nolte F
    Front Immunol; 2021; 12():703574. PubMed ID: 34539634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy.
    Horenstein AL; Bracci C; Morandi F; Malavasi F
    Front Immunol; 2019; 10():760. PubMed ID: 31068926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.
    Drent E; Themeli M; Poels R; de Jong-Korlaar R; Yuan H; de Bruijn J; Martens ACM; Zweegman S; van de Donk NWCJ; Groen RWJ; Lokhorst HM; Mutis T
    Mol Ther; 2017 Aug; 25(8):1946-1958. PubMed ID: 28506593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
    Kassem S; Diallo BK; El-Murr N; Carrié N; Tang A; Fournier A; Bonnevaux H; Nicolazzi C; Cuisinier M; Arnould I; Sidhu SS; Corre J; Avet-Loiseau H; Teillaud JL; van de Velde H; Wiederschain D; Chiron M; Martinet L; Virone-Oddos A
    Blood; 2022 Feb; 139(8):1160-1176. PubMed ID: 35201323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
    Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
    Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.
    Hambach J; Mann AM; Bannas P; Koch-Nolte F
    Front Immunol; 2022; 13():1005800. PubMed ID: 36405759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
    Martin TG; Corzo K; Chiron M; Velde HV; Abbadessa G; Campana F; Solanki M; Meng R; Lee H; Wiederschain D; Zhu C; Rak A; Anderson KC
    Cells; 2019 Nov; 8(12):. PubMed ID: 31779273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD38-specific nanobodies allow
    Pape LJ; Hambach J; Gebhardt AJ; Rissiek B; Stähler T; Tode N; Khan C; Weisel K; Adam G; Koch-Nolte F; Bannas P
    Front Immunol; 2022; 13():1010270. PubMed ID: 36389758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
    Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
    Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD38 as an immunotherapeutic target in multiple myeloma.
    Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F
    Expert Opin Biol Ther; 2018 Dec; 18(12):1209-1221. PubMed ID: 30394809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.